6,771 Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.1% during the 3rd quarter, HoldingsChannel reports. The fund owned 318,608 shares of the biopharmaceutical company’s stock after selling 6,771 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $78,613,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Bank of Nova Scotia lifted its position in shares of Alnylam Pharmaceuticals by 0.6% in the 1st quarter. Bank of Nova Scotia now owns 7,798 shares of the biopharmaceutical company’s stock worth $2,580,000 after acquiring an additional 49 shares during the period. SBI Securities Co. Ltd. boosted its stake in Alnylam Pharmaceuticals by 27.8% during the third quarter. SBI Securities Co. Ltd. now owns 225 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 49 shares in the last quarter. Prestige Wealth Management Group LLC increased its holdings in Alnylam Pharmaceuticals by 30.6% in the 1st quarter. Prestige Wealth Management Group LLC now owns 226 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 53 shares during the period. Fortitude Family Office LLC increased its holdings in Alnylam Pharmaceuticals by 10.5% in the 3rd quarter. Fortitude Family Office LLC now owns 578 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 55 shares during the period. Finally, Glenmede Trust Co. NA raised its stake in shares of Alnylam Pharmaceuticals by 8.3% in the 1st quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 56 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 1.2%

Shares of ALNY opened at $159.89 on Wednesday. The business’s 50 day simple moving average is $233.41 and its 200-day simple moving average is $284.10. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.48 and a quick ratio of 2.43. The company has a market capitalization of $21.42 billion, a P/E ratio of 8.30 and a beta of 0.42. Alnylam Pharmaceuticals, Inc. has a one year low of $156.00 and a one year high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 155.33% and a net margin of 52.85%. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.90 EPS. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ALNY. Bank of America reaffirmed a “buy” rating and set a $287.00 price objective (down from $460.00) on shares of Alnylam Pharmaceuticals in a report on Friday. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Canaccord Genuity Group decreased their price objective on Alnylam Pharmaceuticals from $429.00 to $323.00 and set a “buy” rating on the stock in a report on Monday. Jefferies Financial Group boosted their price target on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a “hold” rating in a research note on Tuesday, September 8th. Finally, UBS Group lowered their price target on Alnylam Pharmaceuticals from $550.00 to $329.00 and set a “buy” rating on the stock in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $305.86.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam plans to present five-year HELIOS-B results and additional clinical and real-world evidence on AMVUTTRA (vutrisiran) at conferences in November. The presentations could provide new information about the treatment’s potential, though the announcement did not include new study results. Alnylam conference presentation announcement
• Negative Sentiment: Analyst sentiment weakened: Raymond James cut its rating from Strong Buy to Outperform, while Bernstein moved from Outperform to Market Perform. Raymond James downgrade Bernstein downgrade
• Negative Sentiment: Price expectations have also been trimmed: the consensus target fell 13.64% to $325.18, and Truist lowered its target to $225 from $315 while cutting its rating to Hold. Although the targets remain above the share price cited in the reports, the reductions signal increased caution. Consensus target reduction

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This trade represents a 12.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.